Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMF-219 in KRAS-Mutated Advanced Solid Tumors
NCT05631574Phase 1Terminated
- Sponsor
- Biomea Fusion
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Covalent Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of icovamenib in non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC) (4 arms), sponsored by Biomea Fusion. Primary endpoint: Optimal Biologic Dose / Recommended Phase 2 Dose at 30 months. Started Jan 2023; status: terminated.
02
Drugs
icovamenib
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05631574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631574.